# US 2021/0171593 A1 · Fusion protein binding to cd47 protein and application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171593 A1
- Document ID: US20210171593A1
- Status: Published application
- Kind: A1
- Application number: 17/048,202
- Filed: 2019-04-16
- Published: 2021-06-10
- Earliest claimed: 2018-04-17
- Assignees: Hangzhou Sumgen Biotech Co., Ltd.; Sumgen Mab (Beijing) Biotech Co., Ltd.
- Applicants: Hangzhou Sumgen Biotech Co., Ltd.; Sumgen Mab (Beijing) Biotech Co., Ltd.
- Inventors: Ming LV; Xiaoran DING; Shiwei MIAO; Bin TAN; Xuegong WANG
- Web page: https://patentgrep.com/patent/US20210171593A1

## CPC

- C07K 14/4703: {Inhibitors; Suppressors}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 11/06: Antiasthmatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/505: {comprising antibodies}
- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C40B 40/02: Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C40B 40/08: Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)

## Abstract

Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10−8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRPα without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

## Claims

### Claim 1

A fusion protein which specifically binds to a CD47 protein and has at least one of the following characteristics:
(a) binding to the CD47 protein with a KD value of 1×10−8 M or lower;
(b) specifically blocking an interaction between the CD47 protein and SIRPα;
(c) not causing a blood clotting reaction; and
(d) inhibiting the growth and/or proliferation of tumors or tumor cells.

### Claim 2 (depends on 1)

The fusion protein according to claim 1, wherein said CD47 protein is a human CD47 protein.

### Claim 3 (depends on 1)

The fusion protein according to claim 1, comprising a human SIRPα domain which can specifically bind to the CD47 protein and an immunoglobulin Fc region, wherein said human SIRPα domain is directly or indirectly linked to the immunoglobulin Fc region.

### Claim 4 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain comprising an extracellular domain of a human SIRPα, its fragment, or its variant which undergoes one or more amino acid substitutions.

### Claim 5 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain comprising an IgV domain of the human SIRPα, its fragment, or its variant which undergoes one or more amino acid substitutions.

### Claim 6 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain comprising a domain of the human SIRPα variant 1, its fragment, or its variant which undergoes one or more amino acid substitutions.

### Claim 7 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain comprising amino acid residues at positions 33-149 of the human SIRPα variant 1, its fragment, or its variant which undergoes one or more amino acid substitutions.

### Claim 8 (depends on 7)

The fusion protein according to claim 7, wherein said mutant comprising amino acid substitutions at one or more residues selected from the group consisting of I61, V63, E77, Q82, K83, E84, V93, D95, D96, K98, N100, R107, G109 and V132.

### Claim 9 (depends on 8)

The fusion protein according to claim 8, wherein said mutant comprising one or more amino acid substitutions selected from the group consisting of R22C, I29L, I61L/V/F, V631, E77I/N/Q/K/H/M/R/N/V/L, Q82S/R/G/N, K83R, E84K/H/D/R/G, V93L/A, D95H/R/E, D96S/T, K98R, N100G/K/D/E, R107N/S, G109R/H and V132L/R/I/S.

### Claim 10 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain comprising an amino acid sequence as set forth in any one of SEQ ID NOS: 1-20, 62-65.

### Claim 11 (depends on 3)

The fusion protein according to claim 3, wherein said immunoglobulin Fc region comprising an Fc region of IgG.

### Claim 12 (depends on 11)

The fusion protein according to claim 11, wherein said IgG is selected from the group consisting of IgG1 and/or IgG4.

### Claim 13 (depends on 3)

The fusion protein according to claim 3, wherein said human SIRPα domain is located at N-terminus of the immunoglobulin Fc region.

### Claim 14 (depends on 3)

The fusion protein according to claim 3, wherein said immunoglobulin Fc region comprising an amino acid sequence as set forth in any one of SEQ ID NOS: 67-68.

### Claim 15 (depends on 1)

The fusion protein according to claim 1, comprising an amino acid sequence as set forth in any one of SEQ ID NOS: 21-61.

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A composition, comprising the fusion protein according to claim 1, and optionally a pharmaceutically acceptable adjuvant.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20)

A method of blocking an interaction between a CD47 protein and SIRPα, said method comprising administering the fusion protein of any one of claims 1-15 or the composition of claim 20.

### Claim 25 (depends on 1, 20)

A method of preventing or treating tumors or autoimmune diseases, comprising administrating the fusion protein of claim 1, and/or the composition of claim 20.

### Claim 26 (depends on 25)

The method according to claim 25, wherein said tumors are selected from the group consisting of CD47-positive hematologic tumors and/or CD47-positive solid tumors.

### Claim 27 (depends on 25)

The method according to claim 25, wherein said autoimmune diseases are selected from the group consisting of Crohn's disease, allergic asthma and/or rheumatoid arthritis.
